Supplementary Information

Phototheranostic Porphyrin Nanoparticles Enable Visualization and Targeted Treatment of Head and Neck Cancer in Clinically Relevant Models

Nidal Muhanna[1,2,‡], Cheng S Jin[1,3,4,‡], Elizabeth Huynh[1,5], Harley Chan[1,2], Yi Qiu[1,3], Wenlei Jiang[1], Liyang Cui[1,5,6], Laura Burgess[1,5], Margarete K. Akens[1,5], Juan Chen[1], Jonathan C Irish[1,2*] , Gang Zheng[1,3,4,5*]*

1. Princess Margaret Cancer Centre and Techna Institute, University Health Network,

Toronto, Canada.

2. Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Canada

3. Department of Pharmaceutical Sciences, University of Toronto, Toronto, Canada

4. Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto,

5. Department of Medical Biophysics, University of Toronto, Toronto, Canada

6. Medical Isotopes Research Center, Peking University, Beijing, China

‡ First two authors contributed equally to this work.

*Corresponding Authors:

 Dr. Gang Zheng, University of Toronto, TMDT 5-354, 101 College Street, Toronto, ON,

M5G 1L7, Canada, E-mail: gang.zheng@uhnres.utoronto.ca

Dr. Jonathan C Irish, University of Toronto, 190 Elizabeth Street, Toronto, Ontario, M5G 2C4, Canada,

E-mail: Jonathan.Irish@uhn.ca

Dr. Juan Chen, UHN, TMDT 5-353, 101 College Street, Toronto, ON, M5G 1L7,

Canada, E-mail: juan.chen@uhnresearch.ca

Figure S1. The size distribution of porphysome. The size was measured in PBS by dynamic light scattering and displayed in volume distribution (%).

Figure S2, The tumor growth curves for porphysome-PTT and control groups were monitored by CT scan. **A**, Porphysome-PTT group - The VX2 tumor was inoculated 12 days prior to PTT (at day -12), porphysomes were intravenously injected at day -1, and PPT was performed at day 0; **B**, PTT laser irradiation only group (without porphysomes injection, n=3); **C**, surgical resection group (n=3).